APA (7th ed.) Citation

Ruan, D., Wu, H., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., . . . Xu, R. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Ruan, Dan-Yun, et al. Garsorasib, a KRAS G12C Inhibitor, with or Without Cetuximab, an EGFR Antibody, in Colorectal Cancer Cohorts of a Phase II Trial in Advanced Solid Tumors with KRAS G12C Mutation. Nature Publishing Group.

MLA (9th ed.) Citation

Ruan, Dan-Yun, et al. Garsorasib, a KRAS G12C Inhibitor, with or Without Cetuximab, an EGFR Antibody, in Colorectal Cancer Cohorts of a Phase II Trial in Advanced Solid Tumors with KRAS G12C Mutation. Nature Publishing Group.